Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559361 | 0.78 | TAAR1 (0.55) | TAAR1IDO1ACHEHRH3MAOB | |
| SCHEMBL933385 | 0.78 | TAAR1 (0.50) | TAAR1IDO1ACHEHRH3MAOB | |
| SCHEMBL95653 | 0.75 | — | — | |
| SCHEMBL5675646 | 0.75 | — | — | |
| SCHEMBL29596752 | 0.74 | TAAR1 (0.74) | TAAR1IDO1ACHEHRH3MAOB | |
| SCHEMBL30000562 | 0.74 | TAAR1 (0.60) | TAAR1IDO1ACHEHRH3MAOB | |
| SCHEMBL1263547 | 0.74 | TAAR1 (0.60) | TAAR1IDO1ACHEHRH3MAOB | |
| SCHEMBL29459538 | 0.74 | TAAR1 (0.60) | TAAR1IDO1ACHEHRH3MAOB | |
| SCHEMBL8096473 | 0.74 | TAAR1 (0.74) | TAAR1IDO1ACHEHRH3MAOB | |
| SCHEMBL5250957 | 0.72 | LPL (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1369405-B1 | PROCESS FOR PRODUCING 1-CHLORO-4-ARYLBUTANE | SUMITOMO CHEMICAL CO (JP) | 2007-09-19 | — | — | EP | disclosed |
| US-6861566-B2 | Process for producing 1-chloro-4-arylbutane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-03-01 | — | — | US | disclosed |
| US-20040097763-A1 | Process for producing 1-chloro-4-arylbutane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1369405-A1 | PROCESS FOR PRODUCING 1-CHLORO-4-ARYLBUTANE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097763-A1 | Process for producing 1-chloro-4-arylbutane | CYP1B1, CBR1, CYP1A1 | TAAR1 77/4885IDO1 114/4885ACHE 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.